Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT)

Bone Marrow Transplantation

Volumn 25, Issue 9, 2000, Pages 957-964

  Voso, M T ^a,b   Martin, S ^c   Hohaus, S ^c   Abdallah, A ^c   Schlenk, R F ^c   Ho, A D ^c   Haas, R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b CATHOLIC UNIVERSITY   (Italy)

^c NONE

Author keywords

Follicular lymphoma; Peripheral blood stem cell transplantation

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0034020271     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702336     Document Type: Article

References (24)

1. Rosenberg SA. Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities. J Clin Oncol 1985; 3: 299-310.
2. Horning SJ. Treatment approaches to the low-grade lymphomas. Blood 1994; 834; 881-884.
3. Johnson PW, Rohatiner AZ, Whelan JS et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20 year study from a single center. J Clin Oncol 1995; 13: 140-147.
4. Hiddemann W, Unterhalt M, Herrmann R et al. Mantle cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998; 16: 1922-1930.
5. Philip T. Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
6. Rohatiner AZ, Johnson PW, Price CG et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177-1184.
7. Haas R, Moos M, Karcher A et al. Sequential high dose therapy with peripheral blood progenitor cell support in low grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 1685-1692.
8. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor prognosis follicular lymphoma. Blood 1995; 86: 3257-3262
9. Freedman AS, Gribben JG, Neuberg D et al. High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-2786.
10. Vose JM, Bierman PJ, Lynch JC et al. Effect of follicularity on autologous transplantation for large cell non-Hodgkin's lymphoma. J Clin Oncol 1998; 16: 844-849.
11. + peripheral blood stem cells (PBSC): retained engraftment capability and reduced tumor cell content. Br J Haematol 1999; 104: 382-391.
12. Bierman PJ, Vose JM, Anderson JR et al. High dose therapy with autologous hematopoietic rescue for follicular low grade non Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445-450.
13. Romaguera JE, McLaughlin P, North L et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 1991; 9: 762-769.
14. Dana BW, Dahlberg S, Nathwani BN et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxoruhicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993; 11: 644-651.
15. Shipp MA, Harrington DP for the International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 987-994.
16. Lopez-Guillermo A, Montserrat E, Bosch F et al. Applicability of the international index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343-1348.
17. Moos M, Schulz R, Martin S et al. The remission status before and the PCR status after high dose therapy with peripheral blood stem cell support are prognostic factors for relapse free survival in patients with follicular non Hodgkin's lymphoma. Leukemia 1998; 12: 1971-1976.
18. Zwicky CS, Maddocks AB, Andersen N, Gribben JG. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 1996; 88: 3314-3322.
19. Widmer L, Pichert G, Jost LM, Stahel RA. Fate of contaminating t(14:18)+ lymphoma cells during ex vivo expansion of CD34 selected hematopoietic progenitor cells. Blood 1996; 88: 3166-3175.
20. Vescio RA, Han EJ, Schiller GJ et al. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 1996; 18: 103-110.
21. Leonard BM, Hetu F, Busque L et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 1998; 91: 331-339.
22. Rohatiner A. Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem cell transplantation. J Clin Oncol 1994; 12: 2521-2523.
23. Kirkland MA, Spencer A, Davidson RJ et al. Quantitation of mafosfamide resistant pre-colony forming units in allogeneic bone marrow transplantation: relationship with rate of engraftment and evidence for long lasting reduction in stem cell numbers. Blood 1996; 87: 3963-3969.
24. Voso MT, Murea S, Goldschmidt H et al. High dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haematopoietic progenitor cell compartment. Br J Haematol 1996; 94: 759-766.